All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Scott Armstrong Named Senior Vice President for Drug Discovery and Chief Research Strategy Officer at Dana-Farber

April 2nd 2024

Scott Armstrong, MD, PhD, has been named senior vice president for drug discovery and chief research strategy officer at Dana-Farber Cancer Institute.

Preliminary Data Hint at PFS Benefit With Personalized Neoantigen Vaccine in Metastatic MSS CRC

April 2nd 2024

Treatment with GRANITE showed early signals of activity following frontline induction chemotherapy in metastatic microsatellite stable colorectal cancer.

FDA to Review Zanidatamab BLA for HER2+ Metastatic Biliary Tract Cancer

April 2nd 2024

A rolling BLA for zanidatamab in previously treated, HER2-positive, advanced biliary tract cancer has been submitted to the FDA.

China’s NMPA Grants Priority Review to Sintilimab Plus Fruquintinib in pMMR/Non–MSI-H Advanced Endometrial Cancer

April 2nd 2024

The new drug application for sintilimab plus fruquintinib has been granted priority review by the NMPA for pMMR/non-MSI-H advanced endometrial cancer.

EMA Accepts MAA for Obecabtagene Autoleucel in R/R B-Cell Acute Lymphoblastic Leukemia

April 2nd 2024

The EMA has accepted a MAA seeking the approval of obe-celf or use in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia.

FDA Accepts BLA for Datopotamab Deruxtecan for Pretreated HR+/HER2– Metastatic Breast Cancer

April 2nd 2024

The FDA has accepted a biologics license application for datopotamab deruxtecan in HR-positive, HER2-negative metastatic breast cancer.

Patient Insurance Status and Out-of-Pocket Costs Affect Genomic Testing Frequency

April 2nd 2024

As genomic testing becomes ubiquitous in cancer care, some patients experience out-of-pocket costs that may affect oncologists’ genetic testing decisions.

A Medical Oncologist’s Insights on Cannabis Use in the Care of Patients With Hematologic Malignancies

April 2nd 2024

Lindsay Wilde, MD, explains when cannabis may be appropriate and how she’s seen the agent affect quality of life for her patients.

Ongoing Research Pushes for Neoadjuvant Alternatives to Chemotherapy in MIBC

April 1st 2024

Bernard H. Bochner, MD, FACS, highlights advancements in early-stage muscle-invasive bladder cancer and the necessity for multimodality approaches.

Durvalumab Plus Guadecitabine Shows PFS Benefit in Cohort of Patients With ccRCC

April 1st 2024

Durvalumab in combination with guadecitabine was tolerable and led to a PFS benefit in patients with checkpoint inhibitor-naive ccRCC.

Evidence-Based Integrative Oncology Approaches Forge a New Path in Cancer Care

April 1st 2024

Richard T. Lee, MD, discusses integrative oncology approaches and the development of the Cherng Family Center for Integrative Oncology at City of Hope.

FDA Approves Danicopan as Add-On Therapy for Extravascular Hemolysis in PNH

April 1st 2024

The FDA has approved danicopan as add-on therapy to ravulizumab or eculizumab for extravascular hemolysis in paroxysmal nocturnal hemoglobinuria.

Ongoing Trials Aim to Build on Systemic Therapy Combinations in Advanced RCC

April 1st 2024

Wenxin (Vincent) Xu, MD, shares recent updates in the treatment of renal cell carcinoma, including insights into ongoing research and trials within the space.

Sylvester Cancer, NANETS Partner to Present Regional Conference on Multidisciplinary Management of Neuroendocrine Tumors

April 1st 2024

Sylvester Comprehensive Cancer Center and NANETS will present a regional educational conference focusing on neuroendocrine tumors.

UTD1 Receives FDA Orphan Drug Designation in Breast Cancer Brain Metastasis

April 1st 2024

Utidelone injectable has received FDA orphan drug designation for patients with breast cancer brain metastases.

Immune Checkpoint Inhibitors Revolutionize Endometrial Cancer Treatment

April 1st 2024

The incorporation of immune checkpoint inhibitors has altered the treatment paradigm for endometrial cancer.

Clinicians Express Reservations Around Ethical Issues of AI in Cancer Care

April 1st 2024

A survey of practicing oncologists in the United States revealed that clinicians have ethical concerns surrounding the use of AI in cancer care.

Recent FDA Approvals in Advanced Urothelial Carcinoma Propel Treatment Forward

March 31st 2024

Daniel P. Petrylak, MD, discusses advancements in the treatment of patients with bladder cancer.

Exploring Disparities in Colorectal Cancer

March 30th 2024

Health systems have put a stronger emphasis on making preventive care accessible, contributing to a reduction in colorectal cancer incidence and mortality.

Establishing Biomarkers Is Key to Driving Personalized Systemic Treatment Choices in Advanced RCC

March 30th 2024

Wenxin (Vincent) Xu, MD, discusses the evolving landscape of systemic therapy in RCC, sharing how he makes treatment decisions amid the changing treatment space.